Consensus revenue is expected to be $0.00 with a projected loss per share of -$0.43, while the current stock price of $3.54 sits slightly below the modest average target of $3.62.
The primary focus for investors is the company’s controversial pivot from cancer therapeutics to Dogecoin mining following its merger with United Dogecoin Inc.
This strategic abandonment of the core oncology pipeline has resulted in a 95% year-over-year reduction in R&D spending to approximately $0.1 million. Additionally, shareholders are awaiting clarity on the company’s plan to resolve a NASDAQ non-compliance notice triggered by delayed financial reporting.